Community Considerations in Relapsed/Refractory Multiple Myeloma: Current and Developing Anti-BCMA Therapies
Post-Test/Evaluation

Questions marked with a * are required

26%

Contact Information

First Name

Last Name

Email Address

Credentials/Degree (MD, DO, RN, etc.)

Date of Participation

Are you a Physician?

Yes

No

TM is a female patient aged 80 years with multiple myeloma refractory to 5 prior lines of therapy. When discussing overall response rate with bispecific antibodies for multiple myeloma based on the latest data, what would be the most accurate assessment of the likelihood of response overall?

A. Approximately 20% to 30%

B. Approximately 40% to 50%

C. Approximately 60% to 80%

D. Approximately 80% to 90%

E. Approximately 90% to 95%

TM is concerned about the potential for cytokine release syndrome and neurotoxicity. Which of the following statements would be most representative of current safety experience with bispecific antibodies in multiple myeloma?

A. The most common serious adverse events with bispecific antibodies are related to cytokine release syndrome

B. Grade 3 or 4 neutropenia, anemia, lymphopenia, and thrombocytopenia are generally more common than grade 3 or 4 cytokine release syndrome with bispecific antibodies

C. Anemia is the most common serious adverse event with bispecific antibodies

D. All bispecific antibodies can cause serious adverse events, with thrombocytopenia being the most common adverse event

E. All bispecific antibodies can cause serious adverse events, with anemia being the most common adverse event

Which of the following bispecific antibody therapies received the first approval in the United States for management of multiple myeloma?

A. Linvoseltamab

B. Alnuctamab

C. Teclistamab

D. Elranatamab

E. Talquetamab

Powered by QuestionPro

Loading...